Clinical trials: Growth Hormone Disorder
Growth Disorders
Saizen® E-Device User Trial
The aim of the study is to evaluate the E-Device performances and handling on the use in common practice, by collecting the impressions of patients, nurses and the investigator on the graphic interface, the instructions manual…
- Trial name
- NCT00450190
- Testing
- Saizen® E-Device
- Volunteers
- 20 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Genetic Disorder, Noonan Syndrome
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the…
- Trial name
- NCT01529944
- Testing
- somatropin
- Where
- Sweden
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
Practicability and Acceptability of Stylomax® in Children
Primary objective: to evaluate the practicability and acceptability of STYLOMAX®, a new injection device for MAXOMAT®, in children, for 1 year.
- Trial name
- NCT00476385
- Testing
- somatropine
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Sanofi
Short Stature, Growth Hormone Deficiency
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
This project is designed to answer the question: Is there an acute IGFBP-3 response in normal children? Our specific hypothesis states that under the influence of growth hormone secretagogues, intact IGFBP-3 molecule will undergo…
- Trial name
- NCT00235599
- Testing
- IGFBP-3 Stimulation Test
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Osteogenesis Imperfecta
Growth Hormone Therapy in Osteogenesis Imperfecta
Growth deficiency is a key feature of severe Osteogenesis Imperfecta (OI) and a frequent feature of mild to moderate forms of the disease. The reason that children with OI are short is not fully understood.
- Trial name
- NCT00001305
- Testing
- Humatrope
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Growth Hormone Deficiency, Small-for-gestational Age
Growth and Asymmetric diMethylArginine
Principal objective : Validation of a handy biochemical parameter, plasma concentration of Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation of the brachial artery, at ultrasound…
- Trial name
- GAMMA (NCT03422081)
- Testing
- arterial doppler ultrasound
- Where
- 2 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Lille
Growth Hormone Deficiency
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
This research study will find out if a new growth hormone stimulation test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children.
- Trial name
- DETECT (NCT04786873)
- Testing
- Macimorelin, Arginine, Clonidine
- Where
- 45 sites in United States, Armenia and 9 more
- Volunteers
- 101 people
- Sponsor
- AEterna Zentaris
Genetic Disorder, Achondroplasia
Special Survey for Long Term Application
This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure…
- Trial name
- NCT01516229
- Testing
- somatropin
- Where
- 2 sites in Japan
- Volunteers
- 395 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency, Idiopathic Short Stature
Constructing an Insulin-Like Growth Factor-based Prediction Model
Serum insulin-like growth factor-I (IGF-I) measurements have been shown to correlate well with growth hormone action and effect, and recent data show that serum IGF-I may be related to safety and efficacy of growth hormone (GH)…
- Conditions
- Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age
- Trial name
- NCT00263445
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
GHD
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive.
- Trial name
- ESCALATE (NCT06024967)
- Testing
- PEG-somatropin
- Volunteers
- 180 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Small for Gestational Age Infant, Silver-Russell Syndrome
Genetic Diagnosis and Human Growth Hormone Treatment in Small for Gestational Age Children With Short Stature
This study is a multi-center, retrospective and non-interventional research. In this study, a total of 150 short children who were small for gestational age and had been treated with recombinant human growth hormone (rhGH) are…
- Conditions
- Small for Gestational Age Infant, Silver-Russell Syndrome, Genetic Diseases, Inborn
- Trial name
- NCT05070234
- Testing
- Blood collection for genetic analysis
- Volunteers
- 150 people
- Sponsor
- Chunxiu Gong
Crohn's Disease
Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease
Of the estimated one million Americans with inflammatory bowel disease (IBD), approximately 20-30% develop this condition during childhood or adolescence, most of whom have Crohn's disease (CD).
- Trial name
- NCT01647412
- Testing
- Growth Hormone, Nutraceutical Combination, Exclusion Diet
- Where
- United States
- Sponsor
- Columbia University
Growth Disorders
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East
This is a Middle East, Multicenter, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in pediatric subjects using easypod™ electromechanical device for growth hormone treatment and to assess the level of…
- Trial name
- ECOS UAE (NCT02015286)
- Testing
- easypod™
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Growth Hormone Deficiency
Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels
The METAB-BELGROW-LAGH study aims to prospectively evaluate the metabolic outcomes of Belgian children diagnosed with growth hormone deficiency (GHD) over a three-year period following the initiation of treatment with either…
- Trial name
- METAB-BELGROW (NCT07173036)
- Testing
- metabolic and auxological outcomes
- Volunteers
- 300 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Growth Disorders
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia
This is a Columbian, Multicentre, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment and to assess the level of…
- Trial name
- ECOS COL (NCT02208076)
- Testing
- easypod™
- Where
- Colombia
- Volunteers
- 44 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diagnosis of GHD With IGF-I/IGFBP-3 Ratio
Growth Hormone (GH) Deficiency & Insulin Like Growth Factor 1 (IGF-I)/ Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio
A 35-month cross-sectional observational study was conducted at an outpatient university hospital in Amman, Jordan. We obtained a comprehensive medical and laboratory evaluation for 134 short-statured children (64 boys and 70…
- Trial name
- NCT02424240
- Testing
- IGF-1/IGFBP-3 ratio
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Jordan
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial.
- Conditions
- Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
- Trial name
- enliGHten (NCT03344458)
- Testing
- TransCon hGH
- Where
- 42 sites in United States, Armenia and 9 more
- Volunteers
- 298 people
- Sponsor
- Ascendis Pharma A/S
Growth Hormone Deficiency
National Cooperative Growth Study in CKD
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.
- Trial name
- NCGS (NCT00616278)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis